What We're Reading: Page 106
Industry reads hand-picked by our editors
Aug 16, 2022
-
The Wall Street Journal
Wall Street Deal Making Faces Greater Scrutiny, Delays Under FTC’s Lina Khan
-
Bloomberg
Burst of Broken SPAC Deals Sends Jitters Through Battered Blank-Check Sector
-
Bloomberg
Can Ketamine Help Alcoholics? This Company Plans to Find Out
-
Reuters
Pfizer CEO Bourla shows mild symptoms after testing positive for COVID
Aug 15, 2022
-
Reuters
Newly-launched U.S. drugs head toward record-high prices in 2022
-
Financial Times
How science is getting closer to a world without animal testing
-
The New York Times
The Long, Long Wait for a Diabetes Cure
Aug 12, 2022
-
The Economist
After a covid-fuelled adrenaline rush, biotech is crashing
-
Reuters
Rotavirus childhood vaccine shortage hits four African countries
-
The New York Times
Hospital and Drugmaker Move to Build Vast Database of New Yorkers’ DNA
-
STAT
Eli Lilly statement on Indiana abortion law sends disingenuous message
Aug 11, 2022
-
Politico
Bottling the monkeypox vaccine could take until early 2023
-
Endpoints News
Cerevel takes the public offering route, with a twist — raising big money thanks to rival data
-
The Atlantic
America’s New Monkeypox Vaccine Strategy Rests on a Single Study
-
Reuters
Aspen COVID vaccine lines risk going idle as J&J orders dwindle
Aug 10, 2022
-
Bloomberg
FDA Warns Diabetes Drug Sitagliptin May Contain Cancer-Causing Carcinogen
-
Nature
Long-COVID treatments: why the world is still waiting
-
ROI-NJ
Catalent to acquire Metrics Contract Services for $475M
-
MIT Technology Review
Psychedelics are having a moment and women could be the ones to benefit
Aug 09, 2022
-
Boston Business Journal
Biogen seeks to shrink real estate in Kendall Square, suburbs
-
Politico
Monkeypox dose sparing? Biden admin looks to NIH-funded study for clues.
-
FierceBiotech
Genentech tries again on diversity aim for Alzheimer’s program
Previous
